Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hull

Showing results (151-160 of 176) with videos related to

Pageof 18
Sort By:
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 16, 2010
Ileal pouch prolapse: prevalence, management, and outcomesMyles R Joyce, Victor W Fazio, Tracy T Hull, et al.
Medrxiv : the Preprint Server for Health Sciences|April 18, 2024
Sensitive Pathogen Detection and Drug Resistance Characterization Using Pathogen-Derived Enzyme Activity Amplified by LAMP or CRISPR-CasQin Wang, Enos C Kline, Shane D Gilligan-Steinberg, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|July 14, 2001
The standardization of terminology for researchers in female pelvic floor disordersA M Weber, P Abrams, L Brubaker, et al.
Work (Reading, Mass.)|February 18, 2017
Use of speech generating devices can improve perception of qualifications for skilled, verbal, and interactive jobsSteven E Stern, Chelsea M Chobany, Alexander A Beam, et al.
International Journal of Clinical Practice|May 10, 2021
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Journal of Child and Adolescent Psychopharmacology|February 18, 2021
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Diagnostic Microbiology and Infectious Disease|June 1, 1987
Pneumocystis carinii pneumonia therapy with 9-deazainosine in ratsJ W Smith, M S Bartlett, S F Queener, et al.
Clinical Therapeutics|March 22, 2021
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled TrialAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Psychopharmacology Bulletin|June 7, 2021
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHDAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
CNS Drugs|July 27, 2022
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Joseph T Hull, Soumya A Chaturvedi, et al.
Pageof 18

Showing results (151-160 of 176) with videos related to

Sort By:
Pageof 18
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 16, 2010
Ileal pouch prolapse: prevalence, management, and outcomesMyles R Joyce, Victor W Fazio, Tracy T Hull, et al.
Medrxiv : the Preprint Server for Health Sciences|April 18, 2024
Sensitive Pathogen Detection and Drug Resistance Characterization Using Pathogen-Derived Enzyme Activity Amplified by LAMP or CRISPR-CasQin Wang, Enos C Kline, Shane D Gilligan-Steinberg, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|July 14, 2001
The standardization of terminology for researchers in female pelvic floor disordersA M Weber, P Abrams, L Brubaker, et al.
Work (Reading, Mass.)|February 18, 2017
Use of speech generating devices can improve perception of qualifications for skilled, verbal, and interactive jobsSteven E Stern, Chelsea M Chobany, Alexander A Beam, et al.
International Journal of Clinical Practice|May 10, 2021
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Journal of Child and Adolescent Psychopharmacology|February 18, 2021
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Diagnostic Microbiology and Infectious Disease|June 1, 1987
Pneumocystis carinii pneumonia therapy with 9-deazainosine in ratsJ W Smith, M S Bartlett, S F Queener, et al.
Clinical Therapeutics|March 22, 2021
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled TrialAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Psychopharmacology Bulletin|June 7, 2021
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHDAzmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
CNS Drugs|July 27, 2022
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Joseph T Hull, Soumya A Chaturvedi, et al.
Pageof 18